PD57-12 THE PROGNOSTIC VALUE OF PROGRAMMED DEATH-LIGAND 1 IN A CHINESE COHORT WITH CLEAR CELL RENAL CELL CARCINOMA

Abstract

You have accessJournal of UrologyKidney Cancer: Advanced (including Drug Therapy) III1 Apr 2018PD57-12 THE PROGNOSTIC VALUE OF PROGRAMMED DEATH-LIGAND 1 IN A CHINESE COHORT WITH CLEAR CELL RENAL CELL CARCINOMA Yuan-Yuan Qu, Wen-Jun Xiao, Hai-Liang Zhang, and Ding-Wei Ye Yuan-Yuan QuYuan-Yuan Qu More articles by this author , Wen-Jun XiaoWen-Jun Xiao More articles by this author , Hai-Liang ZhangHai-Liang Zhang More articles by this author , and Ding-Wei YeDing-Wei Ye More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2018.02.2656AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Programmed death -1 (PD-1) and its ligand programmed death -ligand 1 (PD-L1) have become research hotspots in recent years. New immunotherapies targeting the PD-1/PD-L1 axis were reported to give promising clinical responses in patients with various types of cancer, including renal cell carcinoma (RCC). This study aimed to explore the prognostic value of PD-L1 mRNA expression in tumor tissues for patients with clear cell RCC (ccRCC). METHODS This study enrolled 367 patients treated with radical nephrectomy for ccRCC during the period of 2008 to 2015. Real-time polymerase chain reaction was performed to detect the expression level of PD-L1 in paired cancer tissue and adjacent normal tissue. The relative expression of PD-L1 in ccRCC was measured using the ratio of PD-L1 expression in ccRCC/matched normal tissues. “Low, middle, and high PD-L1 expression” denotes the ratio of PD-L1 mRNA expression in ccRCC/matched normal tissues of less than 1, greater than 1 and less than 3, and greater than 3, respectively. Cox regression models were used to evaluate the prognostic value of all parameters. RESULTS 41 (11.2%), 160 (43.6%) and 166 (45.2%) patients showed low, middle and high expression of PD-L1, respectively. Patients with high PD-L1 expression were more likely to exhibit adverse pathologic features including larger tumor size (P=0.042), advanced T stage (P=0.034), lymph node metastasis (P=0.005), and distant metastasis (P<0.001). High PD-L1 expression comprised 77.5% (31/42) and 60.6% (20/33) of the subgroup with stage IV and grade 4, respectively, while low PD-L1 expression comprised 0% (0/42) and 6.1% (2/33) of the subgroup with stage IV and grade 4, respectively. The multivariate analyses revealed that high or middle PD-L1 expression, lymph node metastasis, distant metastasis, and poor tumor grade were independent prognostic factors of shorter progression-free survival (PFS). Moreover, high or middle PD-L1 expression, advanced T stage, lymph node metastasis, and distant metastasis maintained a significant predictive role for overall survival (OS) after adjusting for covariants. The median PFS for patients with low, middle and high expression of PD-L1 were 86 months (95% CI: 75.1–96.9), 59 months (95% CI: 46.5–71.5) and 50 months (95% CI: 39.7–60.3), respectively. The Kaplan-Meier curves of OS stratified by PD-L1 expression also showed statistically significant difference (P=0.001). CONCLUSIONS Our data suggested that expression of PD-L1 in ccRCC tissue was correlated with prognosis of ccRCC patients. Targeting the PD-1/PD-L1 pathway should be considered in the treatment of ccRCC patients. © 2018FiguresReferencesRelatedDetails Volume 199Issue 4SApril 2018Page: e1071-e1072 Advertisement Copyright & Permissions© 2018MetricsAuthor Information Yuan-Yuan Qu More articles by this author Wen-Jun Xiao More articles by this author Hai-Liang Zhang More articles by this author Ding-Wei Ye More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...